首页> 美国卫生研究院文献>Oxford Open >1367. Clinical Cure in Secondary Efficacy Populations in Patients With Complicated Urinary Tract Infection Treated With ZTI-01 (Fosfomycin for Injection): Findings From the ZEUS Trial
【2h】

1367. Clinical Cure in Secondary Efficacy Populations in Patients With Complicated Urinary Tract Infection Treated With ZTI-01 (Fosfomycin for Injection): Findings From the ZEUS Trial

机译:1367.用ZTI-01(注射用磷霉素)治疗的复杂尿路感染患者继发功效人群的临床治疗:ZEUS试验的结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundZTI-01 (fosfomycin for injection) is an investigational epoxide antibiotic with a differentiated mechanism of action (MOA) inhibiting an early step in bacterial cell wall synthesis. ZTI-01 has a broad spectrum of in vitro activity, including multidrug-resistant Gram-negative pathogens, and is being developed for the treatment of patients with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) in the United States.
机译:背景技术ZTI-01(注射用磷霉素)是一种研究型环氧化物抗生素,具有差异化的作用机制(MOA),可抑制细菌细胞壁合成的早期步骤。 ZTI-01具有广泛的体外活性,包括对多种药物具有耐药性的革兰氏阴性病原体,在美国正在开发用于治疗患有复杂尿路感染(cUTI)和急性肾盂肾炎(AP)的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号